AXL and chronic myelogenous leukemia, BCR-ABL1 positive: The inhibition of AXL expression may potentially lead to the inactivation of downstream signaling pathways (e.g., PI3K, MAPK) involved in enhanced proliferation, the survival of CML cells, and improved drug response [150].